Inhaled Insulin
Afrezza Inhaled Insulin for Type 1 and Type 2 Diabetes
Is the Inhaled-Insulin Afrezza the Real Deal?
After the rapid-acting inhaled insulin Afrezza launched this February, we have been very eager to learn more about how this new product impacts patients’ day-to-day diabetes management. We recently spoke with Ana Ortiz (a type 1 patient) and Bill Kinder (a type 2 patient), two Afrezza users with very different backgrounds...
Does Your Child Dislike Shots? Looking Into Afrezza for Children
New trial testing the inhaled, ultra-rapid insulin in 4-17 year olds.
Sanofi Terminates Partnership for MannKind’s Inhaled Insulin, Afrezza
Goal to maintain access to therapy over next six months. What challenges have been seen to date?